Juno Therapeutics Inc (JUNO)

25.36
0.41 1.60
NASDAQ : Health Care
Prev Close 24.95
Open 25.48
Day Low/High 24.91 / 25.50
52 Wk Low/High 22.37 / 57.82
Volume 692.02K
Avg Volume 1.65M
Exchange NASDAQ
Shares Outstanding 106.02M
Market Cap 2.63B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Juno Therapeutics Reports Fourth Quarter And 2016 Financial Results

Juno Therapeutics Reports Fourth Quarter And 2016 Financial Results

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the fourth quarter...

Juno Therapeutics To Present At March 2017 Investor Conferences

Juno Therapeutics To Present At March 2017 Investor Conferences

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in March.

5 Earnings Short-Squeeze Trade Ideas

5 Earnings Short-Squeeze Trade Ideas

These heavily shorted stocks could get squeezed higher, if they report positive earnings this week.

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite intends to submit a marketing application for KTE-C19 to the U.S. Food and Drug Administration by the end of March.

Juno Therapeutics To Report Full Year And Fourth Quarter 2016 Financial Results On Wednesday, March 1

Juno Therapeutics To Report Full Year And Fourth Quarter 2016 Financial Results On Wednesday, March 1

Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2016, on Wednesday, March 1, 2017, after the close of U.

Juno Therapeutics To Present At The Leerink Partners 6th Annual Global Healthcare Conference

Juno Therapeutics To Present At The Leerink Partners 6th Annual Global Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the Leerink Partners 6 th Annual Global Healthcare Conference at 10:00 a.

Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money

Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money

Stemline's SL-401 has demonstrated robust overall tumor response rates in its clinical trial, but the drug is also now tied to three patient deaths from capillary leak syndrome.

Corsee D. Sanders, Ph.D., Executive Vice President And Head Of Development Operations, Juno Therapeutics (Photo: Business Wire)

Corsee D. Sanders, Ph.D., Executive Vice President And Head Of Development Operations, Juno Therapeutics (Photo: Business Wire)

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Corsee D.

Noteworthy Friday Option Activity: JUNO, SHLD, LJPC

Noteworthy Friday Option Activity: JUNO, SHLD, LJPC

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Juno Therapeutics Inc , where a total of 13,632 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 77.9% of JUNO's average daily trading volume over the past month of 1.7 million shares.

Juno Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference

Juno Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 35 th Annual J.

3 Small Biotechs With Insider Buying

3 Small Biotechs With Insider Buying

Insiders have an edge in this complex sector, so it's worth checking them out.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Juno Therapeutics Defeats Kite Pharma's Challenge To CAR T-Cell Patent

Juno Therapeutics Defeats Kite Pharma's Challenge To CAR T-Cell Patent

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it has defeated an attempt to invalidate a patent...

Federman & Sherwood Reminds Investors Of The Securities Class Action Lawsuit Against Juno Therapeutics, Inc.

Federman & Sherwood Reminds Investors Of The Securities Class Action Lawsuit Against Juno Therapeutics, Inc.

On July 13, 2016, a class action lawsuit was filed in the United States District Court for the Western District of Washington against Juno Therapeutics, Inc.

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

Juno Therapeutics Highlights Progress With Best-in-Class Strategy In B-Cell Malignancies At ASH

Juno Therapeutics Highlights Progress With Best-in-Class Strategy In B-Cell Malignancies At ASH

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today provided an update of key data from studies of its investigational...

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma

Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced encouraging preliminary clinical data for JCAR017 in patients...

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.

Juno Therapeutics Announces Complete Response And Corresponding Early Survival Data For JCAR014 In Patients With Ibrutinib-Refractory CLL

Juno Therapeutics Announces Complete Response And Corresponding Early Survival Data For JCAR014 In Patients With Ibrutinib-Refractory CLL

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced in a presentation at the 58 th American Society of Hematology...

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Cramer wonders if this market has gotten too enthusiastic for the Trump agenda.

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Dow Scores Another Record as Fed Signals a Rate Hike Could Be Coming

Dow Scores Another Record as Fed Signals a Rate Hike Could Be Coming

The Dow closed higher after the minutes from the Federal Reserve's policy-setting meeting indicate that an interest rate hike could come 'relatively soon.'

Dow Clings to Record as Fed Indicates a Rate Hike Could Be Coming

Dow Clings to Record as Fed Indicates a Rate Hike Could Be Coming

The Dow remains higher after the minutes from the Federal Reserve's policy-setting meeting indicate that an interest rate hike could come 'relatively soon.'

On the Hunt for Holiday Movers

On the Hunt for Holiday Movers

I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.

TheStreet Quant Rating: D (Sell)